What Key Growth Drivers Are Shaping The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Forecast Toward $13.15 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Today And What Is Its Future Size?
In recent times, there has been a rapid expansion in the poly (adp-ribose) polymerase (parp) inhibitors market. The market size is anticipated to rise from $6.53 billion in 2024 to $7.49 billion in 2025, displaying a compound annual growth rate (CAGR) of 14.8%. Factors contributing to this growth over the historical period include an increase in cancer cases, a rise in genetic testing, successful clinical trials, expanding insurance coverage, and advancements in cancer research.
The poly (adp-ribose) polymerase (parp) inhibitors market is anticipated to experience swift expansion in the upcoming years, projecting to reach a worth of $13.15 billion by 2029, with a compound annual growth rate (CAGR) of 15.1%. Factors contributing to this growth over the predicted period include increasing production and distribution of medications, escalating cases of BRCA-mutated cancers, a surge in breast cancer prevalence, enhanced usage of monoclonal antibodies, and augmented healthcare spending. The forecast period also identifies key trends such as improvements in biomarker studies, implementation of combination therapies, application of artificial intelligence in pharmaceutical advancements, progress in biomarker-oriented treatment, and the evolution of next-generation PARP inhibitors.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
Which Demand Drivers Are Strengthening The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The increasing incidence of breast cancer is anticipated to stimulate the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market. Breast cancer is a condition characterized by the uncontrolled proliferation of cells in the breast, forming a harmful tumor with the potential to metastasize to other bodily parts. Factors contributing to the escalating incidence of breast cancer include an aging population, alterations in lifestyle, genetic susceptibility, hormonal imbalances, obesity, alcohol intake, and growing exposure to environmental hazards. PARP inhibitors aid breast cancer sufferers by inhibiting the PARP enzyme’s DNA repair function in cancerous cells, resulting in cell death, especially in tumors with BRCA1 or BRCA2 mutations. For example, data from the US-based National Breast Cancer Foundation in January 2025, indicates that one out of every eight women in the United States will be diagnosed with breast cancer in her lifetime. In 2024, diagnoses for invasive breast cancer were given to 310,720 women and 2,800 men. Hence, the escalating incidence of breast cancer is fueling the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
Which Segment Accounts For The Largest Share In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –
1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
Which Disruptive Trends Are Driving Change Across The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Key players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are developing targeted anticancer drugs aimed at genetic mutations found in specific cancers. These drugs work by inhibiting cancer cell growth, preventing spread, or activating immune response. For example, in March 2024, Zydus Lifesciences Limited, an Indian pharmaceutical company, launched IBYRA, a generic PARP inhibitor olaparib, providing an affordable treatment for HRD-positive and BRCA-positive cancers, significantly reducing costs compared to the original drug.
Which Companies Hold A Competitive Edge In The 1583 Market?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market In The Coming Years?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp
Browse Through More Reports Similar to the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025, By The Business Research Company
Her2 Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Checkpoint Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Protein Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
